Join
Live feed
·
PRReleasevia Quantisnow
Agios Pharmaceuticals Inc. logo

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

ByQuantisnow·Wall Street's wire, on your screen.
AGIO· Agios Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AGIO (Agios Pharmaceuticals Inc.) and more on Quantisnow.